Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment ( DrugBank: Xenon )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 85 | Idiopathic interstitial pneumonia | 1 |
85. Idiopathic interstitial pneumonia
Clinical trials : 598 / Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04071769 (ClinicalTrials.gov) | August 3, 2020 | 9/8/2019 | Genentech Xenon MRI Idiopathic Pulmonary Fibrosis | Using Xenon MRI to Evaluate the Efficacy of Therapies for Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment | Duke University | NULL | Recruiting | 18 Years | N/A | All | 20 | Phase 2 | United States |